Suppr超能文献

BRCA1 或 BRCA2 基因突变杂合子携带者中形态正常上皮细胞的基因表达改变。

Altered gene expression in morphologically normal epithelial cells from heterozygous carriers of BRCA1 or BRCA2 mutations.

机构信息

Fox Chase Cancer Center, Philadelphia, PA 19111, USA.

出版信息

Cancer Prev Res (Phila). 2010 Jan;3(1):48-61. doi: 10.1158/1940-6207.CAPR-09-0078.

Abstract

We hypothesized that cells bearing a single inherited "hit" in a tumor suppressor gene express an altered mRNA repertoire that may identify targets for measures that could delay or even prevent progression to carcinoma. We report here on the transcriptomes of primary breast and ovarian epithelial cells cultured from BRCA1 and BRCA2 mutation carriers and controls. Our comparison analyses identified multiple changes in gene expression, in both tissues for both mutations, which were validated independently by real-time reverse transcription-PCR analysis. Several of the differentially expressed genes had been previously proposed as cancer markers, including mammaglobin in breast cancer and serum amyloid in ovarian cancer. These findings show that heterozygosity for a mutant tumor suppressor gene can alter the expression profiles of phenotypically normal epithelial cells in a gene-specific manner; these detectable effects of "one hit" represent early molecular changes in tumorigenesis that may serve as novel biomarkers of cancer risk and as targets for chemoprevention.

摘要

我们假设,在肿瘤抑制基因中携带单个遗传“打击”的细胞表达改变的 mRNA 谱,这可能为可能延迟甚至预防进展为癌的措施确定目标。我们在此报告从 BRCA1 和 BRCA2 突变携带者和对照者培养的原发性乳腺和卵巢上皮细胞的转录组。我们的比较分析确定了两种组织中两种突变的基因表达的多种变化,这通过实时逆转录-PCR 分析独立验证。一些差异表达的基因之前被提议作为癌症标志物,包括乳腺癌中的乳球蛋白和卵巢癌中的血清淀粉样蛋白。这些发现表明,突变肿瘤抑制基因的杂合性可以以基因特异性的方式改变表型正常上皮细胞的表达谱;这种“一击”的可检测效应代表了肿瘤发生中的早期分子变化,可作为癌症风险的新型生物标志物和化学预防的靶标。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/989b/2804937/f82a57d7c2b9/nihms151342f1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验